Abstract: A washing machine is provided with a control panel and is further provided with a connecting part of an intelligent terminal. The connecting part is in data connection with the intelligent terminal and is used for controlling the washing machine by the intelligent terminal. The control panel is of a panel structure which is not provided with a washing program control button, a display screen as well as a peripheral circuit for driving the display screen and the washing program control button. The washing machine is simple and generous in appearance, easy to operate, capable of greatly reducing the production cost and also saving manpower and material resources, and convenient to popularize.

Abstract: There is described herein a method for the electrochemical quantification of a protein analyte in sample, comprising: providing one or more electrode(s), each comprising at least one peptide attached to its surface, the peptide being the protein or a fragment thereof; contacting the sample and electrode with an antibody in the presence of a redox reporter, wherein the antibody is capable of binding to each of the protein analyte and the peptide on the electrode; measuring an electrochemical signal generated by the redox reporter when a potential is applied; quantifying the protein analyte by comparing the electrochemical signal generated with a control, wherein the electrochemical signal is indirectly proportional to the amount of protein analyte in the sample.

Abstract: An organ perfusion device includes an inlet for connection to the organ, and an outlet for connection to the organ. The device also includes a perfusion circuit including: a reservoir configured to hold a perfusion fluid; a waste receptacle, and a plurality of fluid conduits. The fluid conduits define: a delivery fluid path connecting the reservoir with the inlet; a return fluid path, independent of the delivery fluid path, connecting the reservoir with the outlet; and a waste fluid path connecting the reservoir with the waste receptacle. The device also includes a first flow control device configured to selectively prevent or allow fluid flow from the reservoir to the organ via the delivery fluid path; and a second flow control device configured to selectively prevent or allow fluid flow from the reservoir to the waste receptacle via the waste fluid path.

Abstract: A method for recommending clothes collocation and an intelligent terminal. The method is applied to the intelligent terminal. The method includes: a photo album of the intelligent terminal is accessed and clothes are searched for according to occurrence frequencies of the clothes in the photo album; a clothes collocation database is searched according to information of clothes when a preset condition is satisfied; and a recommended collocation solution is displayed.

Abstract: Methods for assaying a donor lung for chronic allograft lung dysfunction (CLAD) optionally bronchiolitis obliterans syndrome (BOS) subtype or restrictive allograft syndrome (RAS) subtype of CLAD or risk of developing BOS subtype or RAS subtype CLAD post-transplant, the method comprising: a. measuring a normalized expression level of an RNA transcript of IL-6 or an expression product thereof in a sample of the donor lung pre-transplant or a normalized expression level of one or more S100 protein, optionally S100A8 and/or S100A9, polypeptide expression product in a sample from the donor lung post-transplant; b.

Abstract: A pharmaceutical composition comprising an ailanthone (AIL) compound or a derivative thereof, for the treatment of diseases or conditions caused by, dependent from, or associated with excessive androgen receptor activity. Ailantone compounds have been discovered to be a potent inhibitor of both full-length AR (AR-FL) and constitutively-active truncated AR splice variants (AR-Vs), and are found to possess favorable drug-like properties such as good bioavailability, high solubility, lack of CYP inhibition, and low hepatotoxicity. Methods of treatment are also provided.

Abstract: A method of classifying a lung graft subjected to normothermic ex vivo lung perfusion (EVLP), during perfusion and/or after perfusion, the method comprising: a) collecting a test sample from the lung graft; b) measuring a polypeptide level of a negative transplant predictor gene product selected from CCG predictor gene products M-CSF, IL-8 SCGF-beta, GRO-alpha, G-CSF, MIP-1 alpha, and/or MIP-1beta, endothelin predictor gene products endothelin 1 (ET-1) and/or big ET-1, and/or apoptosis predictor gene products cytokeratin 18 (CK-18), caspase 3 and/or HMGB-1 in the sample and/or determining a metabolite profile of the sample for lung grafts that are from donors where the death was due to cardiac death (DCD); c) identifying the graft as a good candidate for transplant or a poor candidate for transplant wherein an increased polypeptide level of one or more negative transplant outcome predictor gene products compared to an outcome control or a reference metabolic profile is indicative the graft is a poor candidate

Abstract: An organ perfusion device includes an inlet for connection to the organ, and an outlet for connection to the organ. The device also includes a perfusion circuit including: a reservoir configured to hold a perfusion fluid; a waste receptacle, and a plurality of fluid conduits. The fluid conduits define: a delivery fluid path connecting the reservoir with the inlet; a return fluid path, independent of the delivery fluid path, connecting the reservoir with the outlet; and a waste fluid path connecting the reservoir with the waste receptacle. The device also includes a first flow control device configured to selectively prevent or allow fluid flow from the reservoir to the organ via the delivery fluid path; and a second flow control device configured to selectively prevent or allow fluid flow from the reservoir to the waste receptacle via the waste fluid path.

Abstract: Methods for assaying a donor lung for chronic allograft lung dysfunction (CLAD) optionally bronchiolitis obliterans syndrome (BOS) subtype or restrictive allograft syndrome (RAS) subtype of CLAD or risk of developing BOS subtype or RAS subtype CLAD post-transplant, the method comprising: a. measuring a normalized expression level of an RNA transcript of IL-6 or an expression product thereof in a sample of the donor lung pre-transplant or a normalized expression level of one or more S100 protein, optionally S100A8 and/or S100A9, polypeptide expression product in a sample from the donor lung post-transplant; b.

Abstract: A method of classifying a lung graft subjected to normothermic ex vivo lung perfusion (EVLP), during perfusion and/or after perfusion, the method comprising: a) collecting a test sample from the lung graft; b) measuring a polypeptide level of a negative transplant predictor gene product selected from CCG predictor gene products M-CSF, IL-8 SCGF-beta, GRO-alpha, G-CSF, MIP-1 alpha, and/or MIP-1beta, endothelin predictor gene products endothelin 1 (ET-1) and/or big ET-1, and/or apoptosis predictor gene products cytokeratin 18 (CK-18), caspase 3 and/or HMGB-1 in the sample and/or determining a metabolite profile of the sample for lung grafts that are from donors where the death was due to cardiac death (DCD); c) identifying the graft as a good candidate for transplant or a poor candidate for transplant wherein an increased polypeptide level of one or more negative transplant outcome predictor gene products compared to an outcome control or a reference metabolic profile is indicative the graft is a poor candidate

Abstract: Described are biomarkers and associated methods for identifying a subject having, or at risk of developing, severe illness from influenza. The level of one or more biomarkers in a test sample from the subject is determined and compared to a control level. Optionally, the subject has or is suspected of having H1N1 influenza. In some embodiments the biomarkers may include IL23R, IL10, TNFRSF13B, CX3CR1, CCR2, MAP2K3 and/or IRF1. In some embodiments, the biomarkers include a combination of IL2 and IL23R or IL10 and IL23R. Also described are methods which include determining the level of two or more biomarkers in a sample and multivariate methods are used for comparing the levels in the test sample to the level in a control sample.

Abstract: The invention discloses a metal-bonded diamond grinding wheel prepared by self-propagating pressure-less sintering and a preparation method thereof. The metal bonded diamond grinding wheel mainly comprises a working layer and a non-working layer, wherein the working layer comprises metal bond and grinded diamond, the non-working layer is metal bond, and the metal bond in the working layer and non-working layer have the same components that comprise metal powders of Cu, Al, Ni, Ti, Sn, and Co. To prepare the metal-bonded diamond grinding wheel prepared by self-propagating pressure-less sintering solves the problems of high energy consumption and low manufacture efficiency in the current sintering processes of the metal bonded diamond grinding wheel, and improves the binding force of the metal bond to the grinded diamond by forming carbides between the bond and the grinded diamond.

Abstract: The invention discloses a metal-bonded diamond grinding wheel prepared by self-propagating pressure-less sintering and a preparation method thereof. The metal bonded diamond grinding wheel mainly comprises a working layer and a non-working layer, wherein the working layer comprises metal bond and grinded diamond, the non-working layer is metal bond, and the metal bond in the working layer and non-working layer have the same components that comprise metal powders of Cu, Al, Ni, Ti, Sn, and Co. To prepare the metal-bonded diamond grinding wheel prepared by self-propagating pressure-less sintering solves the problems of high energy consumption and low manufacture efficiency in the current sintering processes of the metal bonded diamond grinding wheel, and improves the binding force of the metal bond to the grinded diamond by forming carbides between the bond and the grinded diamond.

Abstract: Methods and compositions for determining the suitability of a lung for transplantation are described.

Abstract: Effective use of a TGF-? antagonist to treat or to prevent loss of transplant function is described herein. Use of a TGF-? antagonist is demonstrated to effectively prevent loss of organ function in a host due to chronic rejection in which TGF-?-mediated fibroproliferation is a characteristic. Expression in situ of a TGF-? antagonist in the form of a recombinant receptor, i.e., TGF-? type III receptor (TGFBIIIR) showed prevention of bronchiolitis obliterans in comparison to untreated controls in a rat lung transplant model. This provides an effective method for preventing or inhibiting chronic rejection of transplant organs such as lung, kidney, liver and heart in vertebrate hosts including human hosts.

Abstract: The present invention relates to methods and compositions for the treatment of angiogenesis and macular degeneration. In preferred embodiments, the invention relates to the field of eye health. In some embodiments, the invention relates to the prevention and treatment of angiogenesis by administering compounds disclosed herein. In further embodiments, the invention relates to the prevention and treatment of macular degeneration by administering compounds disclosed herein. In still further embodiments, the invention relates to methods and compositions comprising gambogic acid and gambogic acid derivatives.

Abstract: Methods and compositions for determining the suitability of a lung for transplantation are described.

Abstract: Effective use of a TGF-&bgr; antagonist to treat or to prevent loss of transplant function is described herein. Use of a TGF-&bgr; antagonist is demonstrated to effectively prevent loss of organ function in a host due to chronic rejection in which TGF-&bgr;-mediated fibroproliferation is a characteristic. Expression in situ of a TGF-&bgr; antagonist in the form of a recombinant receptor, i.e., TGF-&bgr; type III receptor (TGFBIIIR) showed prevention of bronchiolitis obliterans in comparison to untreated controls in a rat lung transplant model. This provides an effective method for preventing or inhibiting chronic rejection of transplant organs such as lung, kidney, liver and heart in vertebrate hosts including human hosts.